Aelis Farma says data monitoring committee backs continuing AEF0217 Phase 2b Down syndrome trial unchanged

• Aelis Farma’s independent data monitoring committee recommended continuing its Phase 2b AEF0217 trial in Down syndrome with no protocol changes.
• Blinded safety review covered 42 randomized participants; 32 completed at least four weeks as of the June 4, 2026 data cut.
• No serious or severe adverse events reported; all events were mild; investigators did not deem any event treatment-related.
• Enrollment reached 65 randomized participants, about 37% of the planned 188; recruitment target remains end-2026.
• Results are still guided for release in late 2027, subject to completing enrollment and follow-up.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aelis Farma SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260715777415) on July 16, 2026, and is solely responsible for the information contained therein.